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Toll-like receptor (TLR) signaling is a well-character-
ized, innate immune cellular defense mechanism
used to detect and respond to pathogen-associated
molecular patterns (PAMPs). TLR signaling is highly
conserved and has evolved to have both extracellular
and endosomal receptors that recognize PAMPs from
a wide range of microbial pathogens. Recent literature
has emerged to show that activation of TLRs not only
leads to the upregulation of cellular defense mechan-
isms, but also results in upregulation of DNA repair
genes and increased functional DNA repair. Endo-
somal TLR agonists result in increased survival and
repair after both ionizing and UV radiation, suggesting
that the repair pathways for single- and double-strand
breaks are affected. This review brings together these
and other experimental findings to examine how DNA
repair pathways may be linked to TLR signaling. Also
discussed are the varied outcomes and related
physiological implications that increased DNA repair
after injury might have.
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INTRODUCTION
Toll-like receptors (TLRs) are a main component of the innate
immune system that serves as a first line of defense against a
wide range of injurious substances. TLR activation not only
initiates an inflammatory response that works to combat
pathogens, but also potentially results in tissue damage that
must be repaired after the infection is neutralized. Among
humans and mice, there are currently 13 known TLRs, some of
which localize to the cell membrane and are meant to defend
against extracellular pathogens, whereas others are located in
the endosome and detect intracellular pathogens. These
receptors function by recognizing pathogen-associated mole-
cular patterns (PAMPs). Each TLR responds to very specific
PAMPs and initiates the appropriate cellular response to
defend against the pathogen that it has recognized. The
elegant and complex TLR signaling pathways have been the
subject of many well-written and comprehensive reviews, and
hence we will give only a brief overview (Trinchieri and Sher,
2007; Barton and Kagan, 2009; Kawai and Akira, 2011).
Teleologically, it may be of survival value to damaged cells
and the surrounding tissue to have a way of repairing damage
created by TLR-activating agonists, which is the subject of this
review.
All TLRs contain two main signaling domains. The first is an
extracellular or endosomal pathogen-sensing domain that
consists of leucine-rich repeats in the conformation of a
shepherd’s crook, and the second is an intracellular Toll/
interleukin-1 receptor (TIR) domain that interacts with signaling
and adaptor molecules to relay the message that a pathogen has
been sensed. These transmembrane proteins function by either
homodimerizing or heterodimerizing to create a functional
sensing and signaling complex. TLRs 1/2, 2/6, 4/4, and 5/5 are
known to be extracellular sensors as they reside in the plasma
membrane of the cell, whereas TLRs 3/3, 7/7, 8/8, and 9/9 are
considered intracellular sensors as they reside in the membrane
of the endosome. There are also reports of TLRs 2 and 4
localizing to and functioning from the endosome (Dietrich
et al., 2010; Shibata et al., 2011). MyD88 (myeloid differentia-
tion primary response gene (88)) is the necessary adaptor
molecule that interacts with the TIR domain of all TLRs, except
for TLR3, which utilizes TRIF (TIR-domain-containing adapter-
inducing interferon-b) as its sole adaptor molecule to lead to
downstream signaling. TLR4 can use either MyD88 or TRIF to
relay its signal, which is thought to depend on where it is
localized (McGettrick and O’Neill, 2010). The varied location
of and large number of possible signals from TLR4 make it the
most functionally diverse and widely studied TLR. Using distinct
combinations of adaptor and signaling molecules, each TLR
elicits a tailored response to the pathogen that it senses. For an
extensive overview of TLR ligands, both synthetic and naturally
occurring, please refer to the review by Kawai and Akira (2011).
The pathogen-specific response of TLRs involves the release of
cytokines tailored for neutralization of the activating pathogen,
recruitment of necessary immune components by release of
chemokines and upregulation of costimulatory molecules,
regulation of cell cycle, and, when appropriate, mediation of
inflammation (Loegering and Lennartz, 2011; Prince et al.,
2011; Waltz et al., 2011).
TLRs are not only able to sense PAMPs, but they also
respond to damage-associated molecular patterns (DAMPs),
which are endogenous signaling components released by
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cells upon acute damage and/or infection. DAMPs are also
sensed by TLRs present on surrounding cells. The notion that
TLRs are able to recognize and respond to these DAMPs has
become widely recognized and the number of known
DAMPs has grown rapidly over the past few years (Piccinini
and Midwood, 2010). These DAMPs are most notably created
under conditions of oxidative stress, DNA damage, viral
infection, and ischemia/reperfusion (Wheeler et al., 2009;
Huang et al., 2011; Marichal et al., 2011; Tang et al., 2011).
Comprising many categories of molecules, the list of TLR-
activating DAMPs contains proteins/peptides, fatty acids/
lipoproteins, proteoglycans/glycosaminoglycans, and nucleic
acids/nucleic acid–protein complexes. Endogenous DAMPs
have now been identified for all of the TLRs, which are the
subject of many previous reviews that compile lists of known
DAMPs associated with many different environmental and
disease conditions (Krysko et al., 2011; Kuipers et al., 2011;
Miller et al., 2011; Goh and Midwood, 2012; Nace et al., 2012).
Among the currently identified DAMPs that are known to
signal through TLRs, there are a few that are particularly
relevant to this review because they are associated with DNA
damage and DNA-damaging conditions (Table 1). In a mouse
model of hepatic ischemia/reperfusion, endogenous histone
proteins, which are released during DNA-damaging condi-
tions, are shown to activate TLR9 (Huang et al., 2011).
Another DNA-related DAMP is HMGB-1, a chromatin-
binding protein, that is a well-recognized DAMP capable of
signaling through TLRs 2, 4, and 9. This DNA-associated
molecule is implicated in the pathogenesis of a wide range of
diseases including skin cancer, epilepsy, and sepsis (Yu et al.,
2006; Maroso et al., 2010; Mittal et al., 2010). Chromatin and
other self-DNA complexed with proteins/peptides, when
released from the cell, are involved in the pathogenesis of
autoimmune disorders such as systemic lupus erythematosus
and Sjogren’s syndrome. By serving as antigen for autoanti-
body production, antibodies complexed with self-nucleic
acid can then signal through TLRs 7 and 9 to exacerbate
pathogenic inflammation (Rubin et al., 1986; Celhar et al.,
2012). The antimicrobial peptide LL37 has also been shown
to complex with free self-nucleic acids and serves as a TLR7
and TLR8 agonist (Lande et al., 2007; Ganguly et al., 2009).
This aberrant TLR activation has been implicated in the
pathogenesis of psoriasis. Interestingly, a recent publication
shows that UVB-irradiated keratinocytes release damaged
self-noncoding RNAs that serve as potent TLR3 agonists
(Bernard et al., 2012). UVB causes extreme DNA damage that
must be repaired; further experiments should be conducted to
determine whether the described TLR3 activation possibly
leads to increased DNA repair. Simple mislocalization and/or
aberrant release of these ubiquitously present DAMP
molecules can stimulate potentially harmful inflammation
through recognition by TLRs and other pattern recognition
receptors. The ability of the cell to differentiate a genuine
danger signal from a normally functioning molecule speaks of
how tightly regulated the TLR signaling process is. This
review will focus on how activation of TLR pathways might
stimulate increased DNA repair. The aforementioned DAMPs
serve as intriguing venues to investigate whether DAMPs
arising from DNA-damaging conditions may be helping in
initiating repair by signaling through TLRs.
With all of the opportunities present for these TLR
signaling pathways to go awry, it is not surprising that they
are implicated in the pathogenesis of many diseases and are a
target for therapeutics seeking to control the immune
response stimulated by TLR agonists. TLR antagonist therapies
are routinely used and continue to be under development for
treatment of a wide range of diseases including viral
infection, lymphoma, melanoma, systemic lupus erythema-
tosus, and rheumatoid arthritis (Sun et al., 2007; Alexan-
drescu et al., 2010; Ubol and Halstead, 2010; Bourquin et al.,
2011). These drugs target many different parts of the signaling
pathway, including controlling TLR signaling by competitive
inhibition of the ligand binding site and suppression of
homodimerization of the receptors (Park and Youn, 2010; Lee
et al., 2011). Understanding the many complicated and
varied mechanisms of regulation and outcomes from the TLR
signaling pathways will allow for more specific and appro-
priate immune modulation therapy for diseased tissue.
Table 1. Selected DAMPs associated with DNA damage and DNA-damaging conditions1
DAMP
TLR(s)
antagonized Conditions when released Associated organ/disease Reference(s)
Damaged self-noncoding
RNAs
TLR3 UVB irradiation Skin Bernard et al. (2012)
Histone proteins TLR9 Ischemic injury Hepatic ischemia/reperfusion Huang et al. (2011)
HMGB-1 TLR2, TLR4 Oxidative stress, physical injury,
ischemic injury, inflammation
Skin cancer, epilepsy, sepsis Yu et al. (2006); Maroso et al.
(2010); Mittal et al. (2010)
Chromatin-protein
complexes
TLR7, TLR9 Unknown SLE, Sjogren’s syndrome Rubin et al. (1986); Celhar et al.
(2012)
Antimicrobial peptide-
nucleic acid complex
TLR7, TLR8 Cell death Psoriasis Lande et al. (2007); Ganguly
et al. (2009)
Abbreviations: DAMP, damage-associated molecular pattern; HMGB-1, high-mobility group box 1; SLE, systemic lupus erythematosus; TLR, Toll-like
receptor.
1For a more extensive list of DAMPs and their receptor molecules, please refer to the following reviews: Piccinini and Midwood (2010); Krysko et al. (2011);
Kuipers et al. (2011); Miller et al. (2011); Goh and Midwood (2012); and Nace et al. (2012).
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TLR SIGNALING LEADS TO INCREASED DNA REPAIR
Recently, a body of evidence has emerged that shows the
upregulation of DNA repair genes and functional DNA repair
after treatment with TLR agonists. This is initially surprising
because TLR signaling is traditionally thought to defend
against exogenous pathogens by mobilizing an inflammatory
response and by interfacing with adaptive immunity, rather
than leading to increased repair of self-DNA, although, with
our growing knowledge of how TLRs respond to DAMPs,
perhaps increased repair is a logical downstream effect.
Synthetic versions of CpG DNA are the most widely
studied TLR9 ligands because of their clinical relevance
and therapeutic use. In 2008, Zheng et al. (2008), while
investigating the outcomes of TLR9 engagement on g-
irradiated CD4þ T cells as it relates to cancer therapeutics,
observed that CpG DNA–stimulated CD4þ T cells exhibited
increased DNA repair rates after irradiation. They also
showed an increase in the number of cells in the G2 cell-
cycle phase and a decrease in apoptotic cells as measured by
Annexin V staining. This accumulation of cells in the G2
phase of the cell cycle may allow for the increase that is seen
in functional double-strand break (DSB) repair, which
ultimately leads to increased survival and a decrease in
programmed cell death. More recently, a global gene
expression analysis was conducted to investigate which
families of genes are upregulated and downregulated
in vivo upon TLR9 stimulation (Klaschik et al., 2010). This
study finds that, along with several other gene families, there
is a significant increase in mouse splenic mRNAs that code
for proteins involved in the regulation of cell cycles and DNA
repair 5 days after an intraperitoneal injection of CpG DNA.
Although splenomegaly was observed on day 5 of these
experiments, the ratios of B cells, T cells, and monocyte/
macrophages were similar to those of untreated control
spleens, allowing for useful interpretation of gene regulation
results. An in-silico gene expression study, using data sets
collected after intraperitoneal injection of CpG DNA as well
as intranasal inoculation, found similar results; i.e., in
immune cells, genes encoding for DNA repair molecules
are upregulated (Sommariva et al., 2011). The upregulation of
these cell cycle and DNA repair genes helps to support and
explain previous functional findings, and adds to evidence
that stimulation of TLR9 not only leads to a proinflammatory
response but also results in repair of DNA damage.
Although TLRs 7 and 8 are expressed at varied levels in
different tissues and have been shown to activate dendritic
cells in distinct ways, both reside in the membrane of the
endosome and are known to recognize single-stranded RNAs
(Larange et al., 2009). The TLR7 and TLR8 agonist,
Imiquimod, is commonly used as an immune-modulating
topical therapeutic agent to treat dermatologic diseases such
as HPV infection, nonmelanoma skin cancer, and actinic
keratosis (Edwards et al., 1998; Oster-Schmidt, 2004; Hanke
et al., 2010; Swanson et al., 2010). This intracellular TLR
agonist has been found to enhance DNA repair gene
expression as well as functional repair of DNA damage
mechanisms when tested by topical application on the skin of
UV-irradiated mice (Fishelevich et al., 2011). After in vitro
treatment of bone marrow–derived cell lines with Imiquimod,
nucleotide excision repair (NER) gene expression is found to
be increased along with nuclear localization of the repair
molecule, xeroderma pigmentosum, complementation group
A (XPA). Paired with in vivo experiments that show increased
resolution of cyclobutane pyrimidine dimers in UV-irradiated
and Imiquimod-treated mice compared with control-irra-
diated mice, these findings support a more universal role of
TLR stimulation in upregulating functional DNA repair.
Aside from upregulation of traditional DNA repair, the
TLR7 agonist 8-mercaptoguanosine, in conjunction with IL-4,
has been implicated in an increase in class switch recombi-
nation and IgG1 production by B cells (Tsukamoto et al.,
2009). Although it remains unclear whether 8-mercaptogua-
nosine signaling contributes to the DSB repair function
necessary for successful class switch recombination, the
TLR7 agonist helps to initiate B-cell differentiation and
maturation. This observation adds to the growing evidence
that TLR signaling is involved in many more complex
processes than those previously understood as immunomo-
dulatory functions. Treatment with intracellular TLR agonists
for TLR7 and TLR9 seems to result in increased DNA repair
processes by several mechanistic readouts. It is noteworthy
that there are no recent reports of the same findings using
extracellular TLR agonists. However, it has been shown that
pretreatment with Lactobacillus bifidus extract causes an
increase in DNA repair after UV irradiation, which may be a
result of extracellular TLR stimulation by the bacterial extract
(Born and Born, 1987). Although bifidus is commonly
included in antiaging creams for its ability to increase DNA
repair, this property of the compound has still not been
sufficiently confirmed in peer-reviewed literature (Natarajan
et al., 1988). More research is needed to determine whether
this phenomenon of TLR-induced DNA repair is limited to
intracellular TLRs or whether this result can also be induced
by extracellular TLR agonists.
MECHANISMS BY WHICH TLR SIGNALING MIGHT
RESULT IN INCREASED DNA REPAIR
The promoter regions of genes known to be involved in the
NER pathway, which repairs single-strand breaks (SSBs), have
been investigated and a possible link between DNA repair
and TLR signaling has been found. The 50 promoter regions of
all the NER genes studied (ERCC1, XPA, XPB, XPD, XPF, and
XPG) contain at least one putative activator protein-1 (AP-1)
binding site (Zhong et al., 2000). AP-1 is a transcription factor
known to be induced by TLR signaling, and the existence of
its binding sites in promoter regions of many DNA repair
genes suggests evidence of an association between TLR
signaling and increased functional DNA repair (Figure 1).
However, the existence of AP-1 binding sites is not
necessarily the only mechanism of gene regulation and may
not be directly correlated with the observed functional
increase in DNA repair. Experimental models deficient in
TLR and/or AP-1 need to be utilized to determine the
importance of the AP-1 binding site in DNA repair genes and
also to investigate whether TLR-deficient mice have impaired
DNA repair. The TLR signaling pathway, along with its many
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other known functions, may represent a mechanism that the
cell has evolved to coordinately control all of the genes
involved in a necessary response to acute damage. This
phenomenon has been observed in lower prokaryotic
organisms, for example, Saccharomyces cerevisiae, in which
there is a conserved transcription factor–binding sequence in
the promoter of at least 11 DNA repair and metabolism genes
(Xiao et al., 1993). The ability of TLRs to sense DAMPs makes
them ideal candidates for overarching regulation of the DNA
repair process. However, somehow the signal to upregulate
repair must be differentiated from, and balanced between,
the signal to induce a tissue-destructive inflammatory
response. Much research is needed to elucidate which
molecules are involved in this repair response after TLR
signaling and how it might be regulated.
Another way by which TLR activation may upregulate
DNA repair is by initiating the production of cytokines that
act on the cell in an autocrine or paracrine manner
(Figure 1). There are reports that mice with UV-induced
DNA damage show increased repair of this damage when
exogenous IL-12 or IL-18 is injected into the skin (Schwarz
and Schwarz, 2009). The skin of treated and control mice
show the same amount of DNA damage immediately after
UV irradiation, measured by the amount of cyclobutane
pyrimidine dimers; however, 24 hours after UV exposure,
the cyclobutane pyrimidine dimer level is significantly
lower in the skin of cytokine-treated mice versus control.
Increased DNA repair is also seen when exogenous IL-23 is
added to UV-irradiated mice, which might be expected
because of the shared p40 subunit between IL-12 and IL-23
(Majewski et al., 2010). The presence of IL-12, IL-18, or IL-23
is able to stimulate DNA repair mechanisms that result in
increased functional repair, and signaling by many TLRs is
known to initiate production of these, among many other,
cytokines. Interestingly, it has been found that peripheral
blood mononuclear cells from xeroderma pigmentosum (XP)
patients have significantly attenuated IFN-g production
following polyinosinic–polycytidylic acid, a TLR3 agonist,
stimulation (Gaspari et al., 1993). These data can be
interpreted as suggesting impaired TLR3 signaling in XP
patients. This raises the intriguing possibility that impaired
TLR signaling may in some way contribute to the profound
DNA repair defects observed in these patients. It is noteworthy
that the TLR3 signaling pathway uses TRIF as the sole
signaling adaptor molecule; these data may suggest that the
TRIF signaling pathway and the MyD88 signaling pathway
are involved in the upregulation of DNA repair. Upregu-
lation of DNA repair machinery after autocrine signaling by
TLR-induced cytokines may represent a mechanism by which
TLR agonist treatment results in increased DNA repair.
UV radiation–induced cellular damage has been impli-
cated in inducing cell signaling pathways that produce
proinflammatory cytokines that may signal in the previously
described autocrine manner. However, the most commonly
observed UV-induced phenotype is one of immune suppres-
sion (Muthusamy and Piva, 2010; Norval and Halliday,
2011). One of the critical hallmarks of the UV effect that
results in cutaneous immunosuppression is the migration of
antigen-presenting cells impaired by DNA damage to the
local lymph node (Vink et al., 1996). Using a mouse contact
TLR agonists
Extracellular
space
Cytoplasm
Cytokine
receptor(s)
TLR 3/3,
7/7, 9/9
AP-1
Augmentation
of DNA repair
(mechanism
unknown)
– Cytokines (IL-12, IL-23,
others?)
– DNA repair machinery
AP-1
Nucleus
TLR 1/2, 2/6,
5/5, 4/4
Figure 1. Possible direct and indirect mechanisms of transcriptional activation of DNA repair machinery induced by Toll-like receptor (TLR) signaling
pathways.Many genes involved in DNA repair have activator protein-1 (AP-1) binding sites in their promoter regions. Activation of the AP-1 transcription factor
by signaling through the TLR pathway may be a molecular link between TLR agonist treatment and transcriptional control of DNA repair. Autocrine signaling by
cytokines, such as IL-12, made in response to TLR agonist sensing, represents an indirect mechanism by which TLR signaling may increase DNA repair. The
cytokines produced may signal through their appropriate cytokine receptor in an autocrine or paracrine manner to increase transcription of DNA repair genes.
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hypersensitization model, treatment with Imiquimod has
been shown to decrease UV-induced immunosuppression
(Thatcher et al., 2006). UV-irradiated animals that are treated
with the topical TLR7 agonist, Imiquimod, have less DNA
damage in the local draining lymph node when compared with
control-irradiated mice. Increased repair that leads to successful
antigen presentation may be a mechanism whereby this TLR7
agonist is able to counteract UV immunosuppression.
CATEGORIES OF DNA DAMAGE AND ASSOCIATED
MODULATION BY TLR AGONISTS
DNA damage can occur through many routes, including
UV radiation, ionizing radiation, chemical agents, oxidative
stress, and defective receptor editing (Rastogi et al., 2010;
Azzam et al., 2011; Aziz et al., 2012; Dizdaroglu, 2012).
These injurious circumstances result in several types of
damage that lead to varied phenotypic outcomes in the
cell (Table 2). As discussed before, it has become evident
that repair of this range of DNA damage may be increased
upon activation of TLR signaling. UV and ionizing
radiation (g-irradiation) most classically result in SSB and
DSB, respectively. Cyclobutane pyrimidine dimers are
another main damage associated mainly with UVB irradia-
tion (290–320 nm). These dimers require the NER complex
to be excised and corrected, and once this process takes
place the integrity of the affected DNA is maintained.
Because g-irradiation results in DSB that cannot be repaired
using a complementary template, it is associated with
mutagenesis and chromosome abnormalities that often lead
to cell death. Repair of both UV- and g-irradiation has
been shown to be increased after treatment with endosomal
TLR agonists (Zheng et al., 2008; Fishelevich et al., 2011),
implying that both the NER and DSB repair complexes are
stimulated.
Pathogens, although not classically known to directly cause
host DNA damage, can initiate an inflammatory immune
response through TLR signaling that leads to an environment
with increased oxidative stress. This oxidative stress and
associated reactive oxygen species are a prominent cause of
DNA damage, most notably SSB and instability of histones due
to methylation inhibition (Evans and Cooke, 2004). These
conditions are well known to lead to the release of DAMPs that
signal through TLRs on self and surrounding cells. The reactive
oxygen species–induced DAMP signaling classically leads to
inflammation and associated tissue damage; however, condi-
tions of oxidative stress also lead to the eventual repair of
affected tissue (Gill et al., 2010). It is possible that when a
PAMP is sensed by a TLR, DNA-damaging reactive oxygen
species are released, which are then followed by the release of
DAMPs that signal through TLRs to help promote repair;
however, much research is needed to confirm this hypothesis.
OUTCOMES OF INCREASED DNA REPAIR
After unintentional damage by exposure to a genotoxic
agent, increased repair can be a positive outcome for a cell
that has an important putative role in host defense, for
example, an antigen-presenting cell. However, increased
repair in cells that have been programmed for death, that
are infected with a pathogen, or that are being deliberately
targeted for death using a chemotherapeutic drug may
result in an undesirable outcome. For example, if a severely
UV-damaged skin cell repairs itself enough to surpass the
DNA damage checkpoint during cell cycle, growth will not
be arrested and the cell may divide, allowing for propaga-
tion of a mutation that could render the cell cancerous. In
this scenario, it might be advantageous to inhibit TLR
signaling so that repair will not be increased, damage can
be recognized, and the cell deleted. Lewis et al. (2011)
found that TLR4 signaling contributes to UV immune
suppression by promoting T regulatory cell formation.
Therefore, they proposed that TLR inhibition therapy may
prevent dampening of a necessary immune response. They
did not investigate how UV irradiation activated TLR4
signaling, or how the induction of DAMPs may be involved.
The study also did not resolve, on a molecular level, how TLR4
enhanced immune suppression. Nonetheless, this intriguing
finding suggests that TLR and the PAMPs/DAMPs that engage
them could present opposing signals in the setting of genotoxic
Table 2. Mechanisms, types, and possible effectors of DNA damage
Classical phenotype
Hallmark types of damage
induced TLR effect
UV radiation Impaired antigen presentation, immune
suppression, loss of CHS, gradual
formation of mutations
SSB, CBPD TLR7 agonist Imiquimod may enhance repair,
and maintain CHS (Fishelevich et al., 2011)
Ionizing
radiation
Depletion of cells by apoptosis, immune
suppression, heritable gene mutations
DSB, chromosome
abnormalities, mutagenesis
TLR9 agonist CpG DNA increases DNA repair
and cell survival (Zheng et al., 2008)
Chemical agents Cytotoxicity SSB, DSB Antitumor synergy with TLR7 and TLR8 agonist
and cyclophosphamide (Dumitru et al., 2010)
Oxidative stress Tissue and organ damage related to
inflammation
SSB, histone instability Not yet investigated
Receptor editing Defect cause: clonal deletion during
maturation, decreased Ab repertoire
limited adaptive immune response
Abasic site, DSB TLR7 agonist 8-SGuo induces class switch and
IgG1 production (Tsukamoto et al., 2009)
Abbreviations: Ab, antibody; CBPD, cyclobutane pyrimidine dimer; CHS, contact hypersensitization; DSB, double-strand break; 8-SGuo, 8-mercapto-
guanosine; SSB, single-strand break; TLR, Toll-like receptor.
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challenges. Further research is needed to clarify these
apparently divergent outcomes of TLR signaling.
Cancer chemotherapy is another example of a situation
where increased DNA repair is not a favorable outcome.
Such therapy may use DNA-damaging chemotherapeutic
agents targeted to tumor cells to cause cell death. In this
scenario, if repair is increased, the undesirable outcome of
increased survival of tumor cells would be expected.
However, just the opposite has been observed. TLR agonists
have been shown to work synergistically with the che-
motherapeutic drug cyclophosphamide (a known genotoxic
agent) (Dumitru et al., 2010). By mechanisms not yet
elucidated, the TLR agonist sensitizes the tumor cells to
DNA damage, which, given the previously discussed
findings, is not what would be expected. The same
phenomenon is seen in the work by Sommariva et al.
(2011), in which TLR9 agonist treatment caused the
upregulation of DNA repair genes in immune cells but
exactly the opposite in tumor cells, which aided in their
death. Upregulation or downregulation of DNA repair may
represent a molecular biological explanation for the synergy
seen when chemotherapy is administered with TLR agonists
(Larange et al., 2009). These studies suggest that the tumor
microenvironment evolves into an area that is advantageous
for treatment with agents that stimulate TLR signaling. In this
environment, DNA repair in nondiseased cells might be
increased, and in tumor cells DNA repair might be
decreased. These phenomena need further investigation in
order to understand better how immune versus stromal cells,
or normal versus cancerous cells, respond to TLR agonists
and associated DNA repair/cell survival.
DISCUSSION
The paradoxical data discussed in this review imply that
TLR signaling in some environments can lead to increased
DNA repair, whereas in others the opposite might be
true. However, overall, the evidence presented suggests
that the TLR signaling pathways and cell fate might be
connected through the DNA repair pathway. Supporting this
hypothesis, a recent study found that TLR expression is
regulated by DNA metabolic stress and the p53 pathway
(Menendez et al., 2011). Pathogens are well known to
signal through TLRs and cause the subsequent upregulation of
TLR expression; the fact that genotoxic stress and DNA
damage might have the same effect on the TLR pathways is
consistent with the data discussed in this review. If the
molecular signaling pathway of a TLR that leads to promotion
or inhibition of DNA repair, or vice versa, and the conditions
necessary for each outcome can be elucidated, then TLR
modulation could represent a breakthrough in how to control
cell fate, either death or survival, where appropriate. Because
multiple drugs involved in TLR modulation are already
approved for use, elucidation of this pathway and how it
might be related to a wide range of diseases present a unique
opportunity for rapid treatment and observation of a
successful clinical outcome.
More work is needed to determine whether all TLRs are
involved in augmenting DNA repair. TLR and their numerous
agonists (PAMPs and DAMPs) present fine-tuned, tailored
signals at the cellular level, which have profound effects on
shaping the type of immune response that is elicited. Many
more experiments are necessary to investigate whether, in
the case of TLR and DNA repair, the same types of diversity
may be present, resulting in enhanced or decreased DNA
repair, control of cell survival or death, emergence or deletion
of cancer cells, and immune competence or immune suppres-
sion. Figuring out how DNA repair may be involved in resolving
this cell-fate paradox presents an exciting opportunity to
better understand a novel attribute of TLR signaling.
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